207 related articles for article (PubMed ID: 16564235)
1. Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin.
Kanzaki S; Ito M; Takada Y; Ogawa K; Matsuo K
Bone; 2006 Aug; 39(2):414-9. PubMed ID: 16564235
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin.
Kanzaki S; Takada Y; Ogawa K; Matsuo K
J Bone Miner Res; 2009 Jan; 24(1):43-9. PubMed ID: 18715136
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss.
Zehnder AF; Kristiansen AG; Adams JC; Kujawa SG; Merchant SN; McKenna MJ
Laryngoscope; 2006 Feb; 116(2):201-6. PubMed ID: 16467704
[TBL] [Abstract][Full Text] [Related]
4. Impaired vibration of auditory ossicles in osteopetrotic mice.
Kanzaki S; Takada Y; Niida S; Takeda Y; Udagawa N; Ogawa K; Nango N; Momose A; Matsuo K
Am J Pathol; 2011 Mar; 178(3):1270-8. PubMed ID: 21356377
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Nakamura M; Udagawa N; Matsuura S; Mogi M; Nakamura H; Horiuchi H; Saito N; Hiraoka BY; Kobayashi Y; Takaoka K; Ozawa H; Miyazawa H; Takahashi N
Endocrinology; 2003 Dec; 144(12):5441-9. PubMed ID: 14500574
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
8. The Ca
Cao C; Oswald AB; Fabella BA; Ren Y; Rodriguiz R; Trainor G; Greenblatt MB; Hilton MJ; Pitt GS
Bone; 2019 Aug; 125():160-168. PubMed ID: 31121355
[TBL] [Abstract][Full Text] [Related]
9. Influence of osteoprotegerin (OPG) on resorption of heterotopically induced ossicle.
Kochanowska I; Włodarski K; Pienkowski M; Ostrowski K
Cell Tissue Bank; 2004; 5(2):125-8. PubMed ID: 15241009
[TBL] [Abstract][Full Text] [Related]
10. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule.
Zehnder AF; Kristiansen AG; Adams JC; Merchant SN; McKenna MJ
Laryngoscope; 2005 Jan; 115(1):172-7. PubMed ID: 15630389
[TBL] [Abstract][Full Text] [Related]
12. Dissection of the Auditory Bulla in Postnatal Mice: Isolation of the Middle Ear Bones and Histological Analysis.
Sakamoto A; Kuroda Y; Kanzaki S; Matsuo K
J Vis Exp; 2017 Jan; (119):. PubMed ID: 28117786
[TBL] [Abstract][Full Text] [Related]
13. Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice.
Yamazaki H; Sasaki T
J Electron Microsc (Tokyo); 2005 Oct; 54(5):467-77. PubMed ID: 16339792
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.
Bolon B; Carter C; Daris M; Morony S; Capparelli C; Hsieh A; Mao M; Kostenuik P; Dunstan CR; Lacey DL; Sheng JZ
Mol Ther; 2001 Feb; 3(2):197-205. PubMed ID: 11237676
[TBL] [Abstract][Full Text] [Related]
15. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
[TBL] [Abstract][Full Text] [Related]
17. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
[TBL] [Abstract][Full Text] [Related]
19. On the biology of the bony otic capsule and the pathogenesis of otosclerosis.
Bloch SL
Dan Med J; 2012 Oct; 59(10):B4524. PubMed ID: 23158898
[TBL] [Abstract][Full Text] [Related]
20. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
